Home > Oncology > WCLC 2019 > Non-Small-Cell Lung Cancer > Pembrolizumab + chemotherapy beneficial in advanced NSCLC, even without PD-L1 expression

Pembrolizumab + chemotherapy beneficial in advanced NSCLC, even without PD-L1 expression

Conference
WCLC 2019
Trial
KEYNOTE-021, KEYNOTE-189, KEYNOTE 407
Previous research has shown that frontline treatment with pembrolizumab + platinum-based chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC; squamous or non-squamous without epidermal growth factor receptor [EGFR]/anaplastic lymphoma kinase [ALK] mutation) irrespective of PD-L1 expression improves clinical outcomes when compared to standard chemotherapy alone[1-3]. However, more knowledge and insights are required with regard to outcomes for pembrolizumab + chemotherapy in patients without PD-L1 expression as these patients are not eligible for treatment with pembrolizumab monotherapy. Borghaei et al. aimed to put together a pooled analysis of pembrolizumab + chemotherapy in patients with advanced/metastasised NSCLC without PD-L1 expression (tumour proportion score [TPS] <1%) which was based on 3 randomised trials: KEYNOTE-021, KEYNOTE-189, and KEYNOTE 407 [4-6]. These 3 studies held a total of 1,298 patients. Of those, 33.0% had a...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on